Immunological Aspects of Graves' Ophthalmopathy
- PMID: 31781640
- PMCID: PMC6875285
- DOI: 10.1155/2019/7453260
Immunological Aspects of Graves' Ophthalmopathy
Abstract
The body's autoimmune process is involved in the development of Graves' disease (GD), which is manifested by an overactive thyroid gland. In some patients, autoreactive inflammatory reactions contribute to the development of symptoms such as thyroid ophthalmopathy, and the subsequent signs and symptoms are derived from the expansion of orbital adipose tissue and edema of extraocular muscles within the orbit. The autoimmune process, production of antibodies against self-antigens such as TSH receptor (TSHR) and IGF-1 receptor (IGF-1R), inflammatory infiltration, and accumulation of glycosaminoglycans (GAG) lead to edematous-infiltrative changes in periocular tissues. As a consequence, edema exophthalmos develops. Orbital fibroblasts seem to play a crucial role in orbital inflammation, tissue expansion, remodeling, and fibrosis because of their proliferative activity as well as their capacity to differentiate into adipocytes and myofibroblasts and production of GAG. In this paper, based on the available medical literature, the immunological mechanism of GO pathogenesis has been summarized. Particular attention was paid to the role of orbital fibroblasts and putative autoantigens. A deeper understanding of the pathomechanism of the disease and the involvement of immunological processes may give rise to the introduction of new, effective, and safe methods of treatment or monitoring of the disease activity.
Copyright © 2019 Dominika Łacheta et al.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Figures






Similar articles
-
Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.Exp Eye Res. 2016 Jan;142:83-91. doi: 10.1016/j.exer.2015.02.007. Exp Eye Res. 2016. PMID: 26675405 Review.
-
Pathogenesis of ophthalmopathy in autoimmune thyroid disease.Rev Endocr Metab Disord. 2000 Jan;1(1-2):87-95. doi: 10.1023/a:1010020621687. Rev Endocr Metab Disord. 2000. PMID: 11704996 Review.
-
Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors?J Clin Endocrinol Metab. 2011 Aug;96(8):2386-94. doi: 10.1210/jc.2011-0307. Epub 2011 Jun 15. J Clin Endocrinol Metab. 2011. PMID: 21677036 Review.
-
Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves' orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation.Endocrinology. 2013 Sep;154(9):3008-15. doi: 10.1210/en.2013-1576. Epub 2013 Jul 30. Endocrinology. 2013. PMID: 23900776
-
Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.Thyroid. 2007 Oct;17(10):1013-8. doi: 10.1089/thy.2007.0185. Thyroid. 2007. PMID: 17935483 Free PMC article. Review.
Cited by
-
Intravenous rituximab therapy for active Graves' ophthalmopathy: a meta-analysis.Hormones (Athens). 2021 Jun;20(2):279-286. doi: 10.1007/s42000-021-00282-6. Epub 2021 Mar 30. Hormones (Athens). 2021. PMID: 33783712 Review.
-
miR-96-5p Induces Orbital Fibroblasts Differentiation by Targeting Smad7 and Promotes the Development of Thyroid-Associated Ophthalmopathy.Evid Based Complement Alternat Med. 2022 Feb 27;2022:8550307. doi: 10.1155/2022/8550307. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35265151 Free PMC article.
-
T2 Mapping with and without Fat-Suppression to Predict Treatment Response to Intravenous Glucocorticoid Therapy for Thyroid-Associated Ophthalmopathy.Korean J Radiol. 2022 Jun;23(6):664-673. doi: 10.3348/kjr.2021.0627. Epub 2022 Apr 26. Korean J Radiol. 2022. PMID: 35555881 Free PMC article.
-
Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy.Cell Rep Med. 2022 Aug 16;3(8):100699. doi: 10.1016/j.xcrm.2022.100699. Epub 2022 Jul 26. Cell Rep Med. 2022. PMID: 35896115 Free PMC article.
-
Non-coding RNA-mediated epigenetic alterations in Grave's ophthalmopathy: A scoping systematic review.Noncoding RNA Res. 2023 May 16;8(3):426-450. doi: 10.1016/j.ncrna.2023.04.001. eCollection 2023 Sep. Noncoding RNA Res. 2023. PMID: 37324526 Free PMC article.
References
-
- Salvi M., Vannucchi G., Currò N., et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. The Journal of Clinical Endocrinology & Metabolism. 2015;100(2):422–431. doi: 10.1210/jc.2014-3014. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous